Skip to main content
Premium Trial:

Request an Annual Quote

Alison de Bord, Adam Tomasi, Timothy Stultz

Premium
Alta Partners this week announced the promotion of Alison de Bord to director. She joins six other Alta directors responsible for investing at Alta Partners. She currently represents Alta as a director on the boards of Aegerion Pharmaceuticals, Insulet, and SurgRx and was directly involved in Alta’s investments in Esperion Therapeutics and Kerberos Proximal Solutions.
 
De Bord has an MBA from Columbia University and a BA in history from Colgate University.
 
Alta also announced Adam Tomasi has joined the firm as a Kaufman fellow. He had been a student at the Harvard-Massachusetts Institute of Technology Biomedical Enterprise Program and completed his PhD at the University of California, Irvine.
 

 
GWC Technologies announced this week the appointment of Timothy Stultz to its board of directors. Stultz is the president and CEO of Imago Scientific Instruments. Stultz was also the founder and President of Peak Systems and president and CEO of ThauMDx.
 
GWC, based in Madison, Wis., develops and manufactures label-free analysis systems for proteomics, drug discovery, genomics, protein array development, and materials science research.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.